Camber Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Camber Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-600,000	Closed	-$43.7M	–	29
2018 Q4	$43.7M	Buy	+600,000	New	+$46.1M	2.08%	21
2015 Q4	–	Sell	-250,000	Closed	-$20.1M	–	47
2015 Q3	$20.1M	Buy	+250,000	New	+$27.8M	1.72%	19
2013 Q3	–	Sell	-1,000,000	Closed	-$31M	–	34
2013 Q2	$31M	Buy	+1,000,000	New	+$26.6M	3.19%	13

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Camber Capital Management's ALNY Position: Q1 2019 in Review

Camber Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2019, closing a stake of 600,000 shares — an estimated $43.7M sold.

Camber Capital Management first reported a position in ALNY in Q2 2013 and held it in 3 quarters. The position peaked at $43.7M in Q4 2018. 291 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

Camber Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Camber Capital Management sold 600,000 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $43.7M.
Camber Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Camber Capital Management's Alnylam Pharmaceuticals position peaked at $43.7M in Q4 2018.
291 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on Camber Capital Management's 13F filing for Q1 2019, filed 15 May 2019.